Navigation Links
Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:2/4/2008

MADISON, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that it will present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference on Thursday, February 7, 2008 at 10:20 a.m. Eastern Time. Presenting for Wyeth will be Geno Germano, President, U.S. Pharmaceuticals & Women's Health Care, Wyeth Pharmaceuticals.

Wyeth's presentation will be webcast live for investors at http://www.wyeth.com and available for replay following the conference.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
2. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
3. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Declares Preferred Stock Dividend
8. Wyeth Announces Election of New Principal Corporate Officer
9. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
10. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
11. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Jan. 20, 2017 Ginkgo Bioworks, the ... a pioneer in the synthesis and assembly of ... in assembling pathway-length synthetic DNA into Ginkgo,s automated ... in the construction of new organism designs for ... "Gen9 was founded to significantly increase the ...
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter ... The tremendous growth is accounted to two main factors. The first is the ... network of vendors supplying FireflySci products all around the world. , 2016 was a ...
Breaking Biology Technology:
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... Research and Markets has announced the addition ... to 2021" report to their offering. ... The biometric vehicle access system market, ... of 14.06% from 2016 to 2021. The market is estimated to ... 854.8 Million by 2021. The growth of the biometric vehicle access ...
Breaking Biology News(10 mins):